Sjogren’s Syndrome

SAN FRANCISCO – Rituximab is, for now, the first-line option for Sjögren’s syndrome patients with systemic symptoms severe enough to require biologic…
www.rheumatologynews.com|By M. ALEXANDER OTTO

Sjogren's Syndrome US treatment guidelines: Rituximab is first line.


Towards personalised treatment in primary Sjögren's syndrome: predicting response to Rituximab

 
Ann Rheum Dis. 2016 Jan 12. pii: annrheumdis-2015-208304. doi: 10.1136/annrheumdis-2015-208304. [Epub ahead of print]
ncbi.nlm.nih.gov|By Delli K , et al.

A high pretreatment number of CD20+ B cells/mm(2) parotid gland parenchyma predicts better responsiveness of patients with pSS to RTX treatment.

No Comments Yet.

Leave a comment